SME · BSESubscribed: 1,050.21×GMP ₹60
Hamps Bio Limited

Hamps Bio Limited

Hamps Bio Limited(HAMPS)

Total Shares

12,20,000

Issue Size

₹6.22 Cr

Price Band

51 – ₹51

Lot Size

2000 shares

Min. Investment

1,02,000

Max. Investment

1,02,000

Open Date

13 Dec, 2024

Close Date

17 Dec, 2024

Allotment

18 Dec, 2024

Listing

20 Dec, 2024

Announced

13 Dec, 2024

Opening Date

13 Dec, 2024

Closing Date

17 Dec, 2024

Basis of Allotment

18 Dec, 2024

Initiation of Refunds

19 Dec, 2024

Credit of Shares

19 Dec, 2024

Listing Date

20 Dec, 2024

Apply via UPI in 5 minutes

Choose your broker • Zero commission on IPO

About Hamps Bio Limited IPO

Incorporated in 2007, Hamps Bio Limited is engaged in the marketing and distribution of pharmaceutical products like tablets, syrups, capsules, injectables, oil, and nutritional supplements.

The company distributes its products through a network of over 50 distributors and e-commerce platforms, including Amazon (US, Canada, EU), Flipkart, and Jio Mart. Their pharma products are sold in 8 states and union territories, while Freeze-dried and Frozen products reach 6 countries

Hamps Bio Limited IPO Share Price and Issue Size

Issue Breakdown

Total Issue12,20,000 shares₹6.22 Cr
Fresh Issue12,20,000 shares₹6.22 Cr
Offer for Sale0 shares

Shareholding

Pre-Issue31,36,000
Post-Issue43,56,000

Dilution: 38.9% increase in shares

Hamps Bio Limited IPO Financials Health

Hamps Bio Limited IPO Lot Size

ApplicationLotsSharesAmount
Retail Minimum120001,02,000
Retail Maximum120001,02,000
HNI Minimum240002,04,000

(All values in CR)

Hamps Bio Limited IPO Valuation

MetricValue
Debt/Equity0.31
EPS Post IPO1.34
EPS Pre IPO1.6
P/BV2.96
P/E Post IPO38.03
P/E Pre IPO31.94
PAT Margin (%)7.73
ROCE18.31%
ROE21.14%
RoNW14.84%

(All values in CR)

Strength & Risk of Hamps Bio Limited IPO

+Strengths

1. Expert Leadership and Industry Experience driving Strategic Business Growth.

2. Distribution Network with Expansive E-Retailing Presence.

3. Wide and diversified range of products.

4. Diversified, global customer base with long standing relationships.

5. Wide Geographical Presence.

6. Brand Identity.

7. Quality Assurance.

!Risks

1. We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.

2. We do not have our own manufacturing facility for pharmaceutical products and we have to rely on third parties for procuring pharmaceutical products sold by our Company.

3. Our existing manufacturing facility for freeze dried and frozen products is concentrated in a single region i.e., Ankelshwar, Gujarat and the inability to operate and grow our business in this particular region may have an adverse effect on our business, financial condition, results of operations, cash flows and future business prospects.

4. We operate in a highly regulated and controlled industry environment. Our Company operates under several statutory and regulatory permits, licenses and approvals. Our failure to obtain and/or renew any approvals or licenses in future may have an adverse impact on our business operations.

5. Our failure to comply with applicable quality standards may result in product liability claims, which could adversely affect our business, financial condition, cash flows and results of operations.

6. The availability of counterfeit drugs, such as those passed off by others as our products, and the introduction of alternative pharmaceutical products due to changes in technology or consumer needs, could adversely affect our goodwill, results of operations, financial results, and business prospects.

7. Any disruptions to the supply, or increases in the pricing, of the raw materials and finished products that we outsource, may adversely affect the supply and pricing of our products and, in turn, adversely affect our business, cash flows, financial condition and results of operations.

8. Our Group Companies has incurred losses in past financial years.

9. Our Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact our growth and business.

10. We are dependent upon few suppliers for the material requirements of our Freeze dried and Frozen Products business. Further, we do not have definitive agreements or fixed terms of trade with most of our suppliers. Failure to successfully leverage our relationships with existing suppliers or to identify new suppliers could adversely affect our business operations.

Hamps Bio Limited IPO Subscription Status

Investor CategorySubscription (times)Shares OfferedShares bid forTotal Amount (Rs Cr.)
HNI759.695,78,00043,90,98,0002
Market Maker1.0062,00062,0000.32
Retail1.005,80,00077,70,42,0003
Total1.0011,58,0001,21,61,40,0006

Hamps Bio Limited IPO GMP

00.0%

Last updated 11 Dec, 2024 · Source: aggregated grey-market dealers

DateIPO PriceGMPSub2 SaudaEst. ListingEst. ProfitUpdated
11 Dec, 202451₹0--₹51 (0.00%)-11 Dec, 2024
12 Dec, 202451₹2131900₹72 (41.18%)-12 Dec, 2024
13 Dec, 202451₹2131900₹72 (41.18%)-13 Dec, 2024
14 Dec, 202451₹3553200₹86 (68.63%)-14 Dec, 2024
16 Dec, 202451₹4060800₹91 (78.43%)-16 Dec, 2024
17 Dec, 202451₹4568400₹96 (88.24%)-17 Dec, 2024
18 Dec, 202451₹5583600₹106 (107.84%)-18 Dec, 2024
19 Dec, 202451₹5583600₹106 (107.84%)-19 Dec, 2024
20 Dec, 202451₹6091200₹111 (117.65%)-20 Dec, 2024

Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.

How to Apply for Hamps Bio Limited IPO

1

Login to Your Trading App

Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.

2

Go to IPO Section

Find Hamps Bio Limited under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).

3

Enter UPI ID and Submit

Provide your UPI ID linked to your bank account and submit the application.

4

Approve Mandate on UPI App

Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.

5

Application Confirmed

Your funds will be blocked in your account until the IPO allotment process is completed.